BioFactura Revenue and Competitors

Frederick, MD USA

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • BioFactura's estimated annual revenue is currently $6.2M per year.(i)
  • BioFactura's estimated revenue per employee is $155,000

Employee Data

  • BioFactura has 40 Employees.(i)
  • BioFactura grew their employee count by -2% last year.

BioFactura's People

NameTitleEmail/Phone
1
Chairman the Board and Chief Medical OfficerReveal Email/Phone
2
VP Scientific AffairsReveal Email/Phone
3
Director - Process and Drug Product DevelopmentReveal Email/Phone
4
Associate Director Manufacturing OperationsReveal Email/Phone
5
Associate Director Upstream Process DevelopmentReveal Email/Phone
6
Associate Director Manufacturing OperationsReveal Email/Phone
7
Director Quality and Regulatory AffairsReveal Email/Phone
8
Senior Manager Quality ControlReveal Email/Phone
9
Sr Program ManagerReveal Email/Phone
10
Senior Supply Chain ManagerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.3M2-60%N/AN/A
#2
$2.9M38-31%$17.5MN/A
#3
$2.9M38-33%$10.5MN/A
#4
$19.8M1280%$69.4MN/A
#5
$9.6M62-15%N/AN/A
#6
$1.4M90%N/AN/A
#7
$2.5M160%N/AN/A
#8
$7.4M480%N/AN/A
#9
$0.2M1-83%N/AN/A
#10
$1.7M1122%N/AN/A
Add Company

What Is BioFactura?

BioFactura develops and commercializes biodefense drugs, novel drugs, and high-value biosimilars (i.e., follow-on biologics or generic biopharmaceuticals) using its patented StableFastâ„¢ Biomanufacturing Platform, the optimal choice for bringing these products to market with faster, lower cost, superior-quality manufacture. For over 10 years, BioFactura has been advancing life-saving medicines from the research bench to the patient using its innovative drug development and manufacturing technologies. Current and past programs include biodefense drugs against smallpox and Ebola, novel medicines for cancer, and low-cost/high-quality biosimilars for autoimmune and infectious diseases.

keywords:N/A

N/A

Total Funding

40

Number of Employees

$6.2M

Revenue (est)

-2%

Employee Growth %

N/A

Valuation

N/A

Accelerator

BioFactura News

2022-04-19 - Global Poxviridae Infections Drug Market 2022 Research ...

BioFactura, Inc. CEL-SCI Corporation; Chimerix, Inc. China Biologic Products, Inc. CJ HealthCare Corp. EpiVax, Inc. N &...

2022-04-13 - Amgen Releases Positive Phase 3 Results for Stelara Biosimilar

In addition to Amgen, Formycon, Samsung Bioepis, Bio-Thera Solutions, Hikma Pharmaceuticals, Alvotech, BioFactura, and NeuClone are in the...

2022-03-30 - Despite Strong 2021 Performance Headwinds Remain for ...

BioFactura has completed the clinical phase of a pivotal Phase 1 trial for a biosimilar for Janssen's STELARA™, which is a leading treatment for plaque...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$8.6M4011%N/A
#2
$9.3M405%N/A
#3
$9.3M40100%N/A
#4
$8.9M4114%N/A
#5
$10.6M4111%N/A